Eli Lil­ly wins pre­lim­i­nary in­junc­tion in Moun­jaro case in drug­mak­er­s' on­go­ing bat­tle with com­pound­ing phar­ma­cies, well­ness spas

A fed­er­al judge has tem­porar­i­ly blocked a Min­neso­ta med­ical spa from us­ing Eli Lil­ly’s Moun­jaro trade­mark to ad­ver­tise com­pound­ed drugs that con­tain tirzepatide.

Eli Lil­ly and its GLP-1 ri­val No­vo Nordisk have been on a le­gal cam­paign to stop well­ness cen­ters and com­pound­ing phar­ma­cies that they be­lieve are im­prop­er­ly ad­ver­tis­ing the prod­ucts. The pre­lim­i­nary in­junc­tion marks an ear­ly win for Lil­ly, whose fast-sell­ing type 2 di­a­betes drug, al­so known as tirzepatide, was al­so re­cent­ly ap­proved un­der the brand name Zep­bound for weight man­age­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER